Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5% Company Expands OneTest™ Across Firefighter, Occupational Health, Military, and Physician Practice Markets Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) — 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the second quarter ended June 30, 2026. Second Quarter & Subsequent...

Sequential Improvement Across Revenue, Margin, Net Loss and Balance Sheet Management Outlines the Step-Changes Ahead Company Leadership Reaffirm Commitment to Value Creation as Business Momentum Continues COSTA MESA, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a global leader in creator-powered commerce, today provided a business update following the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. The Company’s second-quarter results reflected sequential improvement across nearly every key financial measure compared with the first quarter of 2026. Since quarter-end, Amaze has continued to advance new revenue partnerships and its transformation program, with the Board and management aligned on the Company’s priorities, while...

Differentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term Growth HOUSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) — Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the second quarter ended June 30, 2026 and provided an operational and business update. Second Quarter and First Half 2026 Financial SummaryTotal revenues of approximately $1.77 million and $3.07 million for the second quarter 2026 and first half of 2026, respectively, were each up in excess of 150% versus the comparable 2025 periods Total 2Q product revenues increased 38% sequentially versus 1Q 2026 with Aurix branded product revenues increasing in excess of 30% sequentially Second quarter net operating...

Core Brands Grow 12% While Non-Alcoholic & Functional Revenue More Than Doubles Portfolio Transformation Continues with New Retail Wins, Category Leadership and Functional Expansion Introduces Initial Financial Guidance for Q3, Full-Year 2026 and Fiscal 2027 SANTA MARIA, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) — AMASS Brands Inc. (Nasdaq: AMSS), a premium, multi-category beverage platform spanning non-alcohol, functional, and alcohol 2.0 products, today announced financial results for the second quarter ended June 30, 2026. Financial Highlights for the Second QuarterNet revenue of $5.6 million, up 2% from the prior-year quarter Non-Alcoholic and Functional segment net revenue of $0.4 million, up 132%, driven by Good Twin growth and the launch of AMASS Electrolytes Core brand net revenue up 12%, representing 67% of brand-attributed...

Revenue reached an all-time first-half high of RMB 173.6 billion (up 15% YoY). Core profit attributable to owners of the parent rose 46% to RMB 9.68 billion. Total vehicle sales volume hit 1.42 million units, supported by strong performances across Geely Galaxy, Geely China Star, Lynk & Co and Zeekr. Export volume surged 158% YoY to more than 474,000 units, prompting an increased 2026 exporting target of 920,000 units.HANGZHOU, China, Aug. 17, 2026 (GLOBE NEWSWIRE) — Geely Automobile Holdings Limited (0175.HK, “Geely Auto”) today announced its financial results for the first half of 2026, reporting record sales of more than 1.42 million vehicles. Revenue exceeded RMB 170 billion for the first time, rising 15% year on year to 173.6 billion and marking the group’s sixth consecutive year of first-half revenue growth. Core profit...

Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus”, “Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced its financial results for the six months ending June 30, 2026 and provided a corporate update. “Nasus has made enormous progress in its clinical programs in the first six months of 2026, and we believe it is well positioned to advance to NS002 and NS003 toward key milestones in the second half of the year,” said Brendan O’Grady, Chief Executive Officer of Nasus Pharma. “Building on the positive topline...

Q2 2026 Highlights:Total volume: 888,902 contracts, up 276% from Q1 2026 ADV: 14,572 contracts, up 276% from Q1 2026 Daily average open interest: 641, up 129% from Q1 2026Year-to-Date Highlights (as of June 30, 2026):Total volume: 1,125,040 contracts, up 613% from the last six months of 2025 ADV: 9,222 contracts, up 648% from the last six months of 2025 Daily average open interest: 472, up 28% from the last six months of 2025TORONTO, Aug. 17, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (TSX:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today announced financial and operational results for the second quarter...

Executed on the delivery of a defense-grade, non-China rare earth magnet supply chain: became one of the only known commercial-scale producers with OEM-qualified NdFeB magnet grades and took delivery of the first non-China NdPr metal shipment ahead of the January 1, 2027 DFARS deadline and the July 20, 2026 Executive Order on Securing America’s Defense Supply Chains Launched $100 million financing facility and progressed binding purchase orders for ULVAC sintered magnet production equipment scheduled for November 2026 delivery, supporting the Company’s targeted scale-up to approximately 10,000 metric tons of annual rare earth magnet production capacity Subsequent to quarter-end, strengthened senior leadership with the appointment of Kenji Konishi, former Vice President and Chief Technology Officer of JL MAG Rare Earth, as Head of Magnet...

A total of 13,539 hotels or 1,335,445 hotel rooms in operation as of June 30, 2026. Hotel turnover1 increased 13.2% year-over-year to RMB30.5 billion in the second quarter of 2026. By segments, hotel turnover from the H World China (“HWC”)2 segment increased 15.3% year-over-year in the second quarter of 2026, and hotel turnover from the H World International (“HWI”)3 segment decreased 9.4% year-over-year in the second quarter of 2026. Revenue in the second quarter of 2026 increased 10.8% year-over-year to RMB7.1 billion (US$1.1 billion)4. Manachised and franchised (“M&F”) revenue increased 25.2% year-over-year to RMB3.6 billion (US$529 million) over the same period. Revenue from the HWC segment in the second quarter of 2026 was RMB5.9 billion, which increased 14.9% year-over-year; and HWI segment revenue in the second quarter of...

Banqup Group Announces H1 2026 Results Date and Webcast Invitation  La Hulpe, Belgium – 17 August 2026, 8:00 a.m. CEST – Banqup Group SA (Euronext: BANQ) (Banqup, Company),  a specialized European fintech provider empowering businesses by simplifying financial flows through an innovative, secure platform for e-invoicing, e-payments, e-reporting, and e-trust solutions,  will publish its H1 2026 financial results at 7:00 a.m. CEST on Tuesday, 25 August 2026. Following the release, CEO Koen De Brabander, together with members of Banqup Group’s newly appointed leadership team, will host a webcast at 10:30 a.m. CEST to present Banqup Group’s H1 2026 financial and operational performance, detail progress on the Group’s strategic simplification plan, and conduct a Q&A session for investors and analysts. Executive & Division Leadership...